Entrada Therapeutics, Inc. TRDA
We take great care to ensure that the data presented and summarized in this overview for Entrada Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TRDA
View all-
Baker Bros. Advisors LP New York, NY4.87MShares$41.2 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$37.1 Million56.82% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.26MShares$36.1 Million16.56% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$14.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.6MShares$13.6 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA954KShares$8.08 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny837KShares$7.09 Million0.0% of portfolio
-
Step Stone Group LP La Jolla, CA761KShares$6.45 Million13.01% of portfolio
-
Geode Capital Management, LLC Boston, MA645KShares$5.46 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny594KShares$5.03 Million0.0% of portfolio
Latest Institutional Activity in TRDA
Top Purchases
Top Sells
About TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Insider Transactions at TRDA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2025
|
Kory James Wentworth Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,910
-7.49%
|
$80,190
$9.98 P/Share
|
|
Nov 20
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
28,867
+0.3%
|
$259,803
$9.07 P/Share
|
|
Nov 14
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Direct |
200,000
-6.32%
|
$1,600,000
$8.8 P/Share
|
|
Nov 14
2025
|
Kush Parmar |
SELL
Open market or private sale
|
Indirect |
200,000
-6.32%
|
$1,600,000
$8.8 P/Share
|
|
Nov 12
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
100,736
+1.03%
|
$705,152
$7.84 P/Share
|
|
Nov 11
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
46,434
+0.49%
|
$325,038
$7.47 P/Share
|
|
Nov 10
2025
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
30,874
+0.33%
|
$216,118
$7.22 P/Share
|
|
Sep 02
2025
|
Kory James Wentworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,734
-1.44%
|
$8,670
$5.43 P/Share
|
|
Sep 02
2025
|
Natarajan Sethuraman President, Research & Develop. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,760
-0.88%
|
$8,800
$5.43 P/Share
|
|
Sep 02
2025
|
Nathan J Dowden President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,746
-0.97%
|
$8,730
$5.43 P/Share
|
|
Sep 02
2025
|
Dipal Doshi CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,723
-2.06%
|
$43,615
$5.43 P/Share
|
|
Jul 09
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Indirect |
6,935
-0.63%
|
$48,545
$7.5 P/Share
|
|
Jul 09
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Direct |
20,065
-0.63%
|
$140,455
$7.5 P/Share
|
|
Jul 09
2025
|
Kush Parmar |
SELL
Open market or private sale
|
Indirect |
27,000
-0.63%
|
$189,000
$7.5 P/Share
|
|
Jul 01
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Indirect |
6,422
-0.58%
|
$44,954
$7.12 P/Share
|
|
Jul 01
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Direct |
18,578
-0.58%
|
$130,046
$7.12 P/Share
|
|
Jul 01
2025
|
Kush Parmar |
SELL
Open market or private sale
|
Indirect |
25,000
-0.58%
|
$175,000
$7.12 P/Share
|
|
Jun 30
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Indirect |
6,422
-0.58%
|
$38,532
$6.81 P/Share
|
|
Jun 30
2025
|
5 Am Ventures V, L.P. |
SELL
Open market or private sale
|
Direct |
18,578
-0.58%
|
$111,468
$6.81 P/Share
|
|
Jun 30
2025
|
Kush Parmar |
SELL
Open market or private sale
|
Indirect |
25,000
-0.58%
|
$150,000
$6.81 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 280K shares |
|---|---|
| Exercise of conversion of derivative security | 16.1K shares |
| Open market or private purchase | 207K shares |
| Payment of exercise price or tax liability | 47.7K shares |
|---|---|
| Open market or private sale | 825K shares |